Avricore Health Inc. engages in the health data and point-of-care technologies businesses in Canada and the United Kingdom. It provides HealthTab, a turnkey point-of-care testing platform for pharmacies that can test up to 27 biomarkers on the spot for screening and managing chronic conditions, such as diabetes. The company was formerly known as Vanc Pharmaceuticals Inc. and changed its name to Avricore Health Inc. in October 2018. Avricore Health Inc. was founded in 1996 and is based in Vancouver, Canada.…
HealthTab™ and HeartEye Open New Referral Pathway into Community Pharmacy
Avricore Health (CVE: AVCR) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector.
The shares were at 0.0450 CAD on 20 November 2026, down 35.7% over 52 weeks. Its 52-week range is 0.0400 CAD to 0.1000 CAD: the price is 55.0% below the high and 12.5% above the low.
Its market capitalisation is 5.69M CAD.
Avricore Health reports return on equity of -477.1% and revenue up 170.4% year over year.
It holds more cash than debt, a net cash position of 922.55K CAD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 1 December 2026.